Visiongain publishes Brain Computer Interface Market Report 2020-2030

04 May 2020
Pharma

Visiongain has launched a new pharma report Brain Computer Interface Market Report 2020-2030: Forecasts by Product (Invasive, Partially Invasive, Non Invasive), Application (Healthcare (Disabilities Restoration & Brain Function Repair), Smart Home Control, Communication and Control, Entertainment and Gaming), End Use (Medical, Military, Others), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).

The global brain-computer interface market is anticipated to grow at a lucrative CAGR of xyz% and anticipated to reach USD xyz billion by 2020. Visiongain anticipates that the market is projected to witness lucrative growth rates owing to technological advancements and miniaturization of devices. Brain-computer interfaces (BCI) are increasingly becoming reliable pieces of technology, and beneficial for patients who suffer from paralysis or similar conditions.

To access the data contained in this document please email contactus@visiongain.com

Brain-computer interface (BCI) systems build a communication bridge between the human brain and the external world eliminating the need for typical information delivery methods. BCI helps in sending messages from the human brain and thus decoding it. BCI can help handicapped people via a variety of methods such as in spelling applications, semantic categorization, or silent speech communication. BCIs can also facilitate hands-free applications bringing ease and comfort to human beings through the mind-controlling of machines. They only require incorporating brain signals to accomplish a set of commands and no muscle intervention is needed. BCI assistive robots can offer support for disabled users in daily and professional life, increasing their cooperation in building their community

Continuing innovations in computational and sensor technology are likely to fuel market growth. Additionally, ongoing research to develop treatments for fatal conditions such as brain disorders and injuries, sleep disorders, and cerebrovascular diseases is another factor likely to drive market growth. Also, clinical trials, research institutes, and government agencies have extended their assistance in the form of investments, funds, and grants that have stimulated research activities to boost the use of brain-computer interfaces. The demand for biocompatible materials should also increase the use of a brain-computer interface. The lack of skilled technicians to handle these complex devices is, however, a factor limiting this market's growth.

North America holds the majority of market share followed by Europe and will continue to dominate in the future as a result of several research projects in the region, coupled with funding for research institutes from the government. Also, the market will continue to be driven by the growing number of clinical trials on brain devices across the region. Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to growing healthcare infrastructure and rising disposable income across markets such as India and China. Additionally, unmet needs of patients and untapped nations in this region have been attracting investments by global players and this is expected to boost the Brain-Computer Interface Market growth over the forecast period.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the Brain-Computer Interface Market.

For instance, ANT Neuro recently announced its new and upgraded visor2™ product range. The new and upgraded visor2 product range brings new features such as extended functionality for combined EEG- TMS recordings, multimodality functional mapping of the motor and speech cortex, the integration of the brand-new PowerMAG ANT 100Hz rTMS stimulator and many more improvements.

The comprehensive market report features companies such as Ant Neuro, Brain Products GmbH, Cerora Incorporation, Cognionics, Advanced Brain Monitoring, Inc., Emotiv Incorporation, Guger Technologies Og, Mind Solutions Corporation, Natus Medical Incorporated, Integra Lifesciences Corporation, Neurosky, Neuroelectrics, Nirx Medical Technologies, Nielsen Holding, Interaxon among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever